[go: up one dir, main page]

MX2010013148A - Metodo analitico para supervisar la potencia y estabilidad de las vacunas. - Google Patents

Metodo analitico para supervisar la potencia y estabilidad de las vacunas.

Info

Publication number
MX2010013148A
MX2010013148A MX2010013148A MX2010013148A MX2010013148A MX 2010013148 A MX2010013148 A MX 2010013148A MX 2010013148 A MX2010013148 A MX 2010013148A MX 2010013148 A MX2010013148 A MX 2010013148A MX 2010013148 A MX2010013148 A MX 2010013148A
Authority
MX
Mexico
Prior art keywords
stability
analytical method
vaccine potency
monitor vaccine
monitor
Prior art date
Application number
MX2010013148A
Other languages
English (en)
Inventor
Roerink Frank
Williams Mark
Slightom James
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2010013148A publication Critical patent/MX2010013148A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N2030/042—Standards
    • G01N2030/045—Standards internal
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/74—Optical detectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/86—Signal analysis
    • G01N30/8675—Evaluation, i.e. decoding of the signal into analytical information
    • G01N30/8679—Target compound analysis, i.e. whereby a limited number of peaks is analysed

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se dirige a métodos para evaluar si un antígeno o vacuna se ha degradado con el tiempo utilizando cromatografía líquida. Los métodos aquí descritos también se refieren al uso de cromatografía líquida para evaluar la potencia relativa de un antígeno o vacuna establecida.
MX2010013148A 2008-05-30 2009-05-21 Metodo analitico para supervisar la potencia y estabilidad de las vacunas. MX2010013148A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5734608P 2008-05-30 2008-05-30
PCT/US2009/044775 WO2009146286A1 (en) 2008-05-30 2009-05-21 Analytical method to monitor vaccine potency and stability

Publications (1)

Publication Number Publication Date
MX2010013148A true MX2010013148A (es) 2011-03-21

Family

ID=40905178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010013148A MX2010013148A (es) 2008-05-30 2009-05-21 Metodo analitico para supervisar la potencia y estabilidad de las vacunas.

Country Status (10)

Country Link
US (1) US20110091984A1 (es)
EP (1) EP2285461A1 (es)
JP (1) JP2011522252A (es)
AR (1) AR071931A1 (es)
BR (1) BRPI0913237A2 (es)
CA (1) CA2725450A1 (es)
CL (1) CL2009001323A1 (es)
MX (1) MX2010013148A (es)
TW (1) TW201009337A (es)
WO (1) WO2009146286A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL278096B2 (en) * 2018-04-18 2025-03-01 Biomadison Inc Methods for determining vaccine potency
CN118069976B (zh) * 2024-03-11 2024-08-20 华中科技大学 一种老化sbs改性沥青双组分同步再生剂最佳掺量计算方法
CN120577248B (zh) * 2025-08-04 2025-12-30 艾美坚持生物制药有限公司 基于CpG1018疫苗贮存稳定性的分析方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1233784E (pt) * 1999-12-02 2008-11-03 Novartis Vaccines & Diagnostic Composições e métodos para a estabilização de moléculas biológicas após a liofilização
EP1913956A1 (en) 1999-12-02 2008-04-23 Novartis Vaccines and Diagnostics, Inc. Compositons and methods for stablizing biological molecules upon lyophilization
GB0406013D0 (en) * 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates

Also Published As

Publication number Publication date
CA2725450A1 (en) 2009-12-03
JP2011522252A (ja) 2011-07-28
BRPI0913237A2 (pt) 2016-01-19
WO2009146286A1 (en) 2009-12-03
US20110091984A1 (en) 2011-04-21
CL2009001323A1 (es) 2009-10-23
EP2285461A1 (en) 2011-02-23
AR071931A1 (es) 2010-07-28
TW201009337A (en) 2010-03-01

Similar Documents

Publication Publication Date Title
PH12013502230A1 (en) Multispecific antibodies
PH12017501417A1 (en) Anti-fap antibodies and methods of use
MY154956A (en) Chimeric adenoviral vectors
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
MX372661B (es) Anticuerpos anti-htra1 y metodos de uso.
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
IN2012DN05237A (es)
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
ECSP13012784A (es) Anticuerpos anti-mesotelina e inmunoconjugados
DOP2006000051A (es) Inhibidores de vegf-r2 y métodos
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
CL2012001179A1 (es) Anticuerpo que se une específicamente linfopoyetina estromal tímica (tslp) humana o fragmento de unión a antígeno del mismo; ácido nucleico que lo codifica; vector de expresión; célula huésped; método de producción; composición que lo comprende; y su uso terapéutico como inmunosupresor.
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MX2019001026A (es) Anticuerpos de antihemaglutinina y metodos de uso.
PH12013500616A1 (en) Antibody compositions and methods of use
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
CR20110530A (es) Dispositivo y procedimiento para la verificación y para el análisis cuantitativo de analitos, particularmente de micotoxinas
GB2459609A (en) Methods for allergen detection
MX2013003619A (es) Cuantificacion y caracterizacion de alergenos.
WO2010053769A3 (en) Simultaneous multiple source extended inversion
MX361692B (es) Inhibidores de amida hidrolasa de ácido graso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal